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Abstract
The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large
cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of
deferasirox in this patient population. After 1 year, median serum ferritin decreased significantly from
3254 ng/mL at baseline to 1854 ng/mL (P < .001). Decreases occurred in chelation-naive (3229-1520
ng/mL; P < .001, last-observation-carried-forward analysis), and previously chelated (3263-2585
ng/mL; P = .21, last-observation-carried-forward analysis) patients and were reflective of dose
adjustments and ongoing iron intake. Baseline labile plasma iron levels were within normal range
despite high serum ferritin levels. The most common drug-related adverse events were nausea (22%)
and diarrhea (16%). Serum creatinine increases more than 33% above baseline and the upper limit of
normal occurred in 29 patients (25%), but there were no progressive increases; concomitant use of
cyclosporine had a significant impact on serum creatinine levels. The decrease in mean alanine
aminotransferase levels at 1 year correlated significantly with reduction in serum ferritin (r = 0.40, P <
.001). Mean absolute neutrophil and platelet counts remained stable during treatment, and there were no
drug-related cytopenias. This prospective dataset confirms the efficacy and well characterizes the
tolerability profile of deferasirox in a large population of patients with aplastic anemia. This study was
registered at www.clinicaltrials.gov as #NCT00171821.
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CLINICAL TRIALS AND OBSERVATIONS
Iron chelation therapy with deferasirox in patients with aplastic anemia: a
subgroup analysis of 116 patients from the EPIC trial
Jong Wook Lee,1 Sung-Soo Yoon,2 Zhi Xiang Shen,3 Arnold Ganser,4 Hui-Chi Hsu,5 Dany Habr,6 Gabor Domokos,7
Bernard Roubert,7 and John B. Porter,8 on behalf of the EPIC study investigators
1The Catholic University of Korea, Seoul, South Korea; 2Seoul National University College of Medicine, Seoul, South Korea; 3Ruijin Hospital, Shanghai Second
Medical University, Shanghai, China; 4Medizinische Hochschule Hannover, Hannover, Germany; 5Taipei City Hospital, Taipei, Taiwan; 6Novartis
Pharmaceuticals, East Hanover, NJ; 7Novartis Pharma AG, Basel, Switzerland; and 8University College London, London, United Kingdom
The prospective 1-year Evaluation of Pa-
tients’ Iron Chelation with Exjade (EPIC)
study enrolled a large cohort of 116 patients
with aplastic anemia; the present analyses
evaluated the efficacy and safety of defera-
sirox in this patient population. After 1 year,
median serum ferritin decreased signifi-
cantly from 3254 ng/mL at baseline to
1854 ng/mL (P< .001). Decreases occurred
in chelation-naive (3229-1520 ng/mL;
P < .001, last-observation-carried-for-
ward analysis), and previously chelated
(3263-2585 ng/mL; P .21, last-observation-
carried-forward analysis) patients and were
reflective of dose adjustments and ongoing
iron intake. Baseline labile plasma iron lev-
els were within normal range despite high
serum ferritin levels. The most common
drug-related adverse events were nausea
(22%) and diarrhea (16%). Serum creatinine
increases more than 33% above baseline
and the upper limit of normal occurred in 29
patients (25%), but there were no progres-
sive increases; concomitant use of cyclo-
sporine had a significant impact on serum
creatinine levels. The decrease in mean ala-
nine aminotransferase levels at 1 year corre-
lated significantly with reduction in serum
ferritin (r 0.40, P< .001). Mean absolute
neutrophil and platelet counts remained
stable during treatment, and there were no
drug-related cytopenias. This prospective
dataset confirms the efficacy and well char-
acterizes the tolerability profile of defera-
sirox in a large population of patients with
aplastic anemia. This study was registered
at www.clinicaltrials. gov as #NCT00171821.
(Blood. 2010;116(14):2448-2454)
Introduction
Aplastic anemia (AA) is a rare, potentially life-threatening bone
marrow failure disorder characterized by pancytopenia and an
associated increase in the risk of hemorrhage, infection, organ
dysfunction, and death. Most cases of AA are acquired and
immune-mediated, with a wide geographic distribution.1,2 The
etiology of acquired AA is variable, involving environmental
factors (eg, chemical exposure, medical drug use, infection) and
host genetic risk factors,1 although many cases remain idiopathic.
Treatment with immunosuppressive therapy or hematopoietic stem
cell transplantation can be effective, but many patients with AA
require blood transfusions as supportive therapy. Regular transfu-
sions lead to the development of iron overload, which can cause
significant damage to the heart, liver, and endocrine glands.3,4 The
impact of iron overload-related complications on patient morbidity
and mortality, and the demands they make on medical resources in
patients with AA, have been highlighted in a number of studies.4-7
United Kingdom guidelines for the management of acquired AA
suggest that iron chelation therapy for the treatment of iron
overload should be considered when serum ferritin levels exceed
1000 ng/mL, although patients need to be assessed on an individual
basis.8
Deferoxamine (DFO) is an effective iron chelator, but its
demanding treatment regimen can result in suboptimal compliance,
with ultimate failure to show clinically meaningful decreases in
serum ferritin levels, as well as impaired quality of life.9 A few
studies have been conducted with DFO in patients with AA;
however, these studies only enrolled a small number of patients
(n  1-33); therefore, data with DFO in this population remain
limited.5,10,11 Deferasirox is a once-daily, oral, iron chelator ap-
proved for the treatment of chronic iron overload resulting from
blood transfusions. The effectiveness of deferasirox in reducing or
maintaining body iron has been demonstrated in studies involving
large numbers of patients with a variety of transfusion-dependent
anemias.12,13 Earlier clinical studies of deferasirox have included
smaller populations of patients with AA (n 512 and n 5014).
The largest number of patients with AA ever included in an iron
chelator trial (n 116) were enrolled in the large prospective,
multicenter, 1-year Evaluation of Patients’ Iron Chelation with
Exjade (EPIC) study. Data from the overall EPIC study population
have been published previously.15 The objective of the present
analysis is to specifically evaluate the efficacy and safety of
deferasirox in the patient population with AA.
Methods
A full description of the EPIC study design and inclusion/exclusion criteria
has been previously published15; however, the key information relevant to
this analysis is summarized here.
Study design and dosing schedule
EPIC was a prospective, multicenter, open-label, 1-year study. The
deferasirox starting dose was individualized according to blood transfusion
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frequency. The recommended initial dose was 20 mg/kg per day for patients
receiving approximately 2 to 4 units/month (7-14 mL/kg per month for a
body weight of approximately 60 kg, equivalent to 0.3 to 0.5 mg/kg per day
of iron) of packed red blood cells. Initial doses of 10 or 30 mg/kg per day
could be considered for patients receiving less or more frequent blood
transfusions, respectively. Specific dose adjustments in steps of 5 to 10 mg/kg
per day up to 40 mg/kg per day were allowed based on quarterly serum
ferritin trends and continuous assessment of safety markers (including
serum creatinine, liver function tests, skin rash, and auditory and ocular
disturbances). Dose increases were recommended in patients with baseline
serum ferritin values of more than 500 ng/mL who had an upward trend or
patients with baseline serum ferritin values of more than 1000 ng/mL who
had no downward trend after 3 months. Dose escalation to more than
40 mg/kg per day was permitted in exceptional circumstances and had to be
approved individually by the Study Monitoring Committee. If serum
ferritin levels fell to less than or equal to 500 ng/mL on 2 consecutive study
visits, deferasirox treatment was suspended until levels exceeded 500 ng/mL.
Key inclusion and exclusion criteria
In total, 1744 iron-overloaded patients with various transfusion-dependent
anemias, including patients with AA, were enrolled. Male or female
patients (age,  2 years) with transfusional iron overload were included in
the study if they fulfilled the following criteria: serum ferritin levels more
than or equal to 1000 ng/mL, or less than 1000 ng/mL but with a history of
multiple transfusions ( 20 transfusions or 100 mL/kg of red blood cells)
and R2 magnetic resonance imaging-confirmed liver iron concentration
(LIC) of more than or equal to 2 mg Fe/g dry weight. Patients were
excluded from the study if they had a life expectancy of less than 1 year,
alanine aminotransferase (ALT) levels of more than 300 U/L or serum
creatinine levels above the upper limit of normal (ULN), or a history of
nephrotic syndrome. Patients (or parents/guardians) provided written,
informed consent before entering the study, which was conducted in
accordance with Good Clinical Practice guidelines and the Declaration of
Helsinki. The study was approved by an Institutional Review Board/
Independent Ethics Committee/Research Ethics Board at each participating
site. A Study Monitoring Committee supervised the trial conduct and made
decisions regarding dose adjustments for individual patients who were
outside of those outlined in the protocol.
Assessments
Serum ferritin was assessed every 4 weeks. Efficacy endpoints included the
change in serum ferritin level from baseline to 52 weeks, the relationship
between serum ferritin levels and other surrogate markers of iron overload,
as well as changes in labile plasma iron (LPI) pre- to post-deferasirox
administration. The correlation between changes from baseline in serum
ferritin and ALT was also assessed as a post hoc analysis. Blood samples to
assess changes in LPI levels were taken before administration (ie, at
predicted daily peak) and 2 hours after administration of deferasirox, at
baseline and at weeks 12, 28, and 52. Iron intake was derived based on the
volume of transfused blood given and its concentration (ie, the hematocrit),
and the amount of iron present in a red cell, using a prespecified and
validated formula that has been described in more detail elsewhere.16 Safety
was evaluated by regular monitoring and recording of all adverse events
(AEs) and serious AEs, routine laboratory testing (including hematology,
blood chemistry, and urine renal function assessments), and medical
physical examination during study visits.
Statistical methods
Efficacy was assessed for the full analysis set, including all patients who
had been successfully screened and started the study. If there was no serum
ferritin value available at 52 weeks, the last available observation was used
as the end of study assessment to calculate change from baseline (last-
observation-carried-forward analysis), thereby providing a robust yet
conservative endpoint to cope with the intention-to-treat principle. The
correlation between change from baseline in serum ferritin versus ALT was
assessed using Pearson correlation coefficients and regression analysis. All
patients who received at least 1 dose of study medication were included in
the safety population. The reported P values were based on 2-sided
significance tests (Student t test).
Results
Patient characteristics and disposition
In total, 116 patients with AA were enrolled in the EPIC study
(Table 1). These patients had been receiving transfusions for a
mean duration of more than 6 years, yet more than two-thirds had
never received iron chelation therapy. In the overall AA population,
median serum ferritin level at baseline was 3254 ng/mL; baseline
levels in chelation-naive and previously chelated patients were
3229 and 3263 ng/mL, respectively.
In total, 88 patients (75.9%) with AA completed the 1-year
study (Figure 1). Of the 28 patients (24.1%) who discontinued,
18 (22.8%) of 79 were chelation-naive and 10 (27.0%) of 37 were
previously chelated; reasons for discontinuation were similar in
both groups. Thirteen patients (11.2%) discontinued because of the
occurrence of AEs: 9 discontinuations were the result of AEs
assessed by the investigator to be related to study drug (including
Table 1. Demographic and baseline patient characteristics
Characteristic Patients with AA (n  116)
Mean age  SD, y 33.3  17.1
Age group, y
2 to less than 16, n (%) 16 (13.8)
16 or older, n (%) 100 (86.2)
Male/female, n 67:49
Race (White/Black/Asian), n 32:4:80
Chelation-naive, n (%) 79 (68.1)
Previous iron chelation therapy, n (%)
DFO monotherapy 31 (26.7)
DFO  deferiprone combination 6 (5.2)
Mean duration of previous iron chelation
therapy  SD, y
4.3  5.8
Mean duration of transfusion history  SD, y 6.1  5.7
Mean no. of transfusion sessions in the year
before study entry  SD
12.5  13.0 (n  114)
Mean total volume red blood cells transfused
in the year before study entry  SD, mL/kg
116  179 (n  112)
Median baseline serum ferritin (range), ng/mL 3254 (908-25 346) (n  115)
Figure 1. EPIC study patient disposition.
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skin rash [n 4], hearing loss, nausea, upper abdominal pain,
anorexia, abnormal serum creatinine levels), whereas 4 were the
result of non–drug-related AEs (including pyrexia, leg fracture,
subdural hematoma, and alcohol abuse). Investigators assessed that
2 patients no longer required study drug because of rapidly
decreasing serum ferritin levels. The discontinuation resulting from
abnormal laboratory values was the result of elevated serum
creatinine levels and febrile neutropenia. Six patients withdrew
consent; however, the investigators were not obliged to comment
on the reasons for withdrawal, so no additional statement can be
made about these discontinuations. Five patients died of non-
treatment-related causes, including sepsis (n 3), pneumonia and
hepatic rupture (n 1 for both).
Deferasirox dosing and iron intake
At the beginning of the study, 2 patients (1.7%) initially received a
deferasirox dose of 10 mg/kg per day, 113 (97.4%) received
20 mg/kg per day, and 1 (0.9%) received 30 mg/kg per day. During
the study, deferasirox dose was adjusted on 1 or more occasion in
85 patients (73.3%). Doses were increased 19 times in 17 patients,
(14.7%) at a median of 21 weeks (range, 8-49 weeks) after
treatment initiation. Doses were reduced in 31 patients (26.7%)
because of laboratory abnormalities or AEs, most commonly
abnormal serum creatinine levels (n 10), skin rash (n 5), and
diarrhea (n 4). Laboratory abnormalities or AEs led to temporary
drug interruptions in 52 patients (44.8%). Among the 88 patients
who completed 12 months of treatment, 26 (29.5%) were receiving
deferasirox less than 20 mg/kg per day at the end of the study,
50 (56.8%) were receiving more than or equal to 20 to less than
30 mg/kg per day, and 12 (13.6%) were receiving more than or
equal to 30 mg/kg per day. Over the course of the 1-year treatment
period, the average actual dose of deferasirox was 17.6 plus or
minus 4.8 mg/kg per day; 75 (64.7%) and 41 (35.3%) patients
received average actual doses of less than 20 and more than or
equal to 20 to less than 30 mg/kg per day, respectively.
During the treatment period, patients received a mean of
66.1 plus or minus 47.2 mL red blood cells/kg, equivalent to
0.25 plus or minus 0.19 mg/kg per day of iron. Mean transfusional
iron intake was significantly different between patients who
received an average actual deferasirox dose of less than 20 and
more than or equal to 20 to less than 30 mg/kg per day (0.21 vs
0.31 mg/kg per day, respectively, P  .006, Wilcoxon 2-sided test).
Effect of deferasirox on serum ferritin levels
After 1 year of treatment, median serum ferritin levels decreased in
the overall AA patient group from 3254 ng/mL at baseline to
1854 ng/mL, representing a significant decrease of 964 ng/mL
(n  115, P  .001; Table 2) based on last-observation-carried-
forward analysis.
Median serum ferritin levels at baseline were similar in patients
who received average actual deferasirox doses of less than 20 and
more than or equal to 20 to less than 30 mg/kg per day, although
patients in the less than 20 mg/kg per day group had a lower mean
iron intake (Table 2). Serum ferritin levels decreased comparably in
the 2 dose groups over 1 year of treatment; however, the decrease
was significant in the less than 20 mg/kg per day group (P  .001)
but not in the more than or equal to 20 to less than 30 mg/kg per
day group (Table 2; Figure 2). Patients in the more than or equal to
20 to less than 30 mg/kg per day dose group had higher iron intake
during the study, hence the need for higher doses to achieve a
comparable reduction in serum ferritin. Median serum ferritin
decreased from baseline to 1 year in both chelation-naive (3229-
1520 ng/mL, n 79; P  .001) and previously chelated patients
(3263-2585 ng/mL, n 37; P  .21).
Change in LPI with deferasirox treatment
LPI data were available for 104 patients with AA. LPI levels before
deferasirox administration were within normal limits (ie,  0.4M)17
throughout the study and were decreased after deferasirox administra-
tion at baseline (0.23-0.01M), week 12 (0.08-0.01M), week 28
(0.06-0.01M), and week 52 (0.04-0.03M).
Relationship between serum ferritin and ALT
Mean serum ALT at baseline, 3, 6, 9, and 12 months was 62.5 plus
or minus 50.7, 54.5 plus or minus 66.7, 41.1 plus or minus 40.3,
42.5 plus or minus 41.5, and 35.4 plus or minus 29.2 U/L,
respectively. After 12 months of deferasirox treatment, there was a
significant mean decrease from baseline in ALT of 26.8 plus or
minus 42.9 U/L (P  .001); the decrease in the less than 20 and
more than or equal to 20 to less than 30 mg/kg per day dose
categories was 30.4 plus or minus 48.4 (P  .001) and 20.4 plus or
minus 30.7 U/L (P  .371), respectively. There was a significant
correlation between the absolute change in serum ferritin and ALT
(r  0.40, P  .001), which indicated that a decrease in serum
Table 2. Change from baseline in median serum ferritin by average actual dose
Average actual deferasirox dose
< 20 mg/kg/d (n  75) > 20-< 30 mg/kg/d (n  41) All (n  116)
Baseline serum ferritin, ng/mL 3263 (908-18 635) 3238 (1129-25 346) 3254 (908-25 346)
Serum ferritin at 1 y, ng/mL 1819 (212-14 509) 2191 (87-17 233) 1854 (87-17 233)
Absolute change in serum ferritin, ng/mL* 970 (11 753 to7883) 884 (15 704 to13 894) 964 (15 704 to13 894)
P  .001  .278  .001
Mean iron intake  SD, mg/kg/d 0.21  0.18 0.31  0.20 0.25  0.19
Serum ferritin data are median (range).
*Based on last-observation-carried-forward analysis.
Table 3. Most common (> 5% overall) drug-related AEs by dose
group
< 20 mg/kg/d
(n  75),
no. (%)
> 20-< 30 mg/kg/d
(n  41),
no. (%)
All (n  116),
no. (%)
Nausea 19 (25.3) 7 (17.1) 26 (22.4)
Diarrhea 10 (13.3) 8 (19.5) 18 (15.5)
Rash 9 (12.0) 4 (9.8) 13 (11.2)
Vomiting 9 (12.0) 1 (2.4) 10 (8.6)
Dyspepsia 8 (10.7) 1 (2.4) 9 (7.8)
Abdominal pain 5 (6.7) 2 (4.9) 7 (6.0)
Upper abdominal pain 4 (5.3) 3 (7.3) 7 (6.0)
Anorexia 6 (8.0) 1 (2.4) 7 (6.0)
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ferritin of 500 ng/mL was associated with a decrease in ALT of
17.4 U/L.
Safety of deferasirox
Irrespective of the relationship with study drug, AEs were reported
in 110 patients with AA (94.8%); the most common AEs were
gastrointestinal (69.0%) and infections (59.5%). Sixty-four patients
(55.2%) experienced AEs that were considered by the investigator
to be drug related, the most common of which were gastrointestinal
symptoms, such as nausea, diarrhea, and vomiting, as well as skin
rash (Table 3). Drug-related AEs were observed in 44 (58.7%) and
20 (48.8%) patients who received actual deferasirox doses of less
than 20 and more than or equal to 20 to less than 30 mg/kg per day,
respectively. Most drug-related AEs were mild to moderate in
nature (96.6%) and did not lead to study discontinuation. There
were no serious AEs considered by the investigators to be drug
related. Eleven patients underwent a dose reduction because of the
occurrence of an AE, which was considered to be drug related in
5 patients (nausea, vomiting, rash, increased serum creatinine,
increased ALT). Two patients (1.7%) had an increase in ALT more
than 10 ULN on 2 consecutive visits: 1 patient was receiving a
dose of 20 mg/kg per day and the other 30 mg/kg per day at the
time of the increase. Both patients had elevated ALT levels at
baseline, and neither underwent a dose reduction because of
elevated ALT levels. In general, there was no difference in the AE
profile between chelation-naive and previously chelated patients.
Change in serum creatinine
Twenty-nine patients (25.0%) had 2 consecutive serum creatinine
increases more than 33% above baseline, which also exceeded the
ULN; 28 of these had normal serum creatinine levels at baseline.
Of the 29 patients, 20 (26.7%) of 75 and 9 (22.0%) of 41 received
actual doses of less than 20 and more than or equal to 20 to less than
30 mg/kg per day and 22 (27.8%) of 79 and 7 (18.9%) of 37 were
chelation-naive and previously chelated, respectively. There were
no progressive increases in the mean serum creatinine over time.
Two consecutive serum creatinine increases more than 33% above
baseline and ULN were observed in 10 of 21 patients (47.6%)
receiving concomitant cyclosporine treatment, compared with
19 of 95 patients (20.0%) not receiving cyclosporine (P  .001;
Table 4). In a logistic regression model to assess factors potentially
influencing serum creatinine levels, which also considered gender,
age, and mean actual deferasirox dose, concomitant cyclosporine
use was the only variable that reached statistical significance
(P  .03). The odds ratio for the relative risk of having an event of
2 consecutive values increased by more than 33% and more than
ULN was 3.14 for patients on concomitant cyclosporine. Ten
patients had their dose of deferasirox reduced because of an
increase in serum creatinine, and 4 of these patients were receiving
cyclosporine; the last creatinine value assessed was within the
normal range in 8 of these patients, including 3 of the 4 patients
receiving cyclosporine.
Other safety parameters
Five patients (4.3%) had ear disorders, only 1 of which (moderate
deafness) was considered by the investigator to be related to study
drug. There were 15 patients (12.9%) with eye disorders, none of
which was considered related to study drug. Mean absolute
neutrophil and platelet counts remained stable over the course of
the study (Figure 3), and there were no cases of drug-related
cytopenias in any patients with AA. Mean hemoglobin levels were
maintained between 9 and 10 g/dL throughout deferasirox treatment.
Figure 2. Mean deferasirox dose ( SD) and median change
in serum ferritin ( 25th/75th percentiles), by average actual
dose categories (full analysis set). (A) All patients. (B) Dose
less than 20 mg/kg per day. (C) Dose more than or equal to 20 to
less than 30 mg/kg per day.
Table 4. Patients with increase in serum creatinine more than 33%
above baseline on 2 consecutive visits and/or serum creatinine
above ULN, with and without concomitant cyclosporine use
Cyclosporine
use n (%)
Two values
> ULN,*
no. (%)
Two
consecutive
values
> 33%,*
no. (%)
Two
consecutive
values
> 33% and
> ULN,*
no. (%)
No cyclosporine 95 (82) 8 (8.4) 34 (35.8) 19 (20.0)
Concomitant
cyclosporine
21 (18) 3 (14.3) 3 (14.3) 10 (47.6)†
Total 116 (100) 11 (9.5) 37 (31.9) 29 (25.0)
*Categories are mutually exclusive.
†P  .001 versus patients with no concomitant use of cyclosporine.
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Discussion
Previous clinical evaluation of deferasirox in patients with AA has
been limited to a few studies in small numbers of patients;
however, these studies have demonstrated the potential for defera-
sirox to decrease iron burden in this population.12,14 These findings
have been confirmed in this large study of 116 iron-overloaded
patients with AA, in which 1 year of treatment with deferasirox
resulted in a statistically significant and clinically relevant reduc-
tion in serum ferritin levels that was reflective of dose adjustments
and mean iron intake during the study. Baseline serum ferritin
levels and the reduction in serum ferritin over the 1-year treatment
period were similar in patients who received average actual
deferasirox doses of less than 20 mg/kg per day or more than or
equal to 20 to less than 30 mg/kg per day. However, the decrease
was not significant in patients in the more than or equal to 20 to less
than 30 mg/kg per day dose group, who needed higher doses
because they were receiving higher iron intake than those in the
less than 20 mg/kg per day dose group. These data support the
clinical approach in patients with AA of selecting deferasirox
starting dose based on transfusion requirements; appropriate dose
titration at 3-month intervals based on serum ferritin levels and
safety markers should subsequently be performed. This observa-
tion is in agreement with conclusions made based on the assess-
ment of data from other patient types enrolled in the EPIC study.
Nevertheless, there remains some debate regarding the clinical
complications of transfusional iron overload and subsequently the
need for chelation therapy in patients with AA and other bone
marrow failure disorders. Although this has only been clearly
demonstrated in patients with 	-thalassemia, most patients with
AA will receive supportive care with blood transfusions8; toxic iron
as a result of chronic transfusion therapy is expected to affect
organs similarly in AA patients. In addition, survival rates are
relatively long in transfused AA patients,18 leaving them at
increased risk of developing iron overload and its related complica-
tions. This was highlighted in a survey by the Korean Iron
Overload Study Group in patients with AA and myelodysplastic
syndromes (MDS) with a history of more than 20 units of blood
transfusions. A substantial proportion of patients were iron over-
loaded (331 of 1128 patients surveyed) despite the availability of
DFO, and many of these patients (97 of 331 patients) also had
organ damage.5 Serum ferritin levels correlated with the number
and duration of transfusions, as well as the duration of transfusion
dependence. In the EPIC study, AA patients had median baseline
serum ferritin levels of more than 2500 ng/mL, which is known to
be associated with significant negative outcomes.19,20 For the
patients who had been previously chelated, these data suggest that
prior chelation practices were not providing adequate management
of their iron burden. Together with the lack of prior chelation
therapy in more than two-thirds of patients, these data suggest that
the need to treat iron overload, and its potential complications, may
be underappreciated in the AA population. Further and longer-term
data are needed to more fully evaluate the efficacy and safety of
chelation therapy and to assess the impact on morbidity and
mortality.
In the present study, after 1 year of deferasirox treatment,
median serum ferritin levels had fallen to less than 2500 ng/mL in
chelation-naive patients and were close to 2500 ng/mL in previ-
ously chelated patients. Data from this trial are based on the
preplanned analysis of absolute change in serum ferritin from
baseline. Although the assessment of serum ferritin has limitations
(eg, levels can be increased under certain conditions such as
infection and inflammation), it is simple and inexpensive and,
when assessed serially, generally provides a reliable tool to assess
total body iron and response to chelation therapy. In addition, the
relationship between long-term control of serum ferritin and
survival has been clearly demonstrated in cohort studies of chelated
patients with thalassemia major.20-23 Advanced technologies, such
as noninvasive magnetic resonance imaging, are becoming more
available for measuring iron burden; however, the use of this
technique in clinical practice is currently somewhat limited as the
necessary equipment is not widely available and specific methods
and calibrations are required. There is evidence of a relationship
between changes in serum ferritin and LIC with deferasirox therapy
in a range of transfusional iron overload conditions.12 Therefore,
the serial measurement of serum ferritin remains the most acces-
sible method and the one most widely used in clinical practice for
determining iron overload and monitoring chelation therapy in
many parts of the world.
Liver dysfunction is one of the major complications of iron
overload in patients with AA,4 and elevated serum ALT is an
important indicator of hepatocellular injury that can potentially
progress to cirrhosis. In this cohort of AA patients, the observed
reduction in serum ferritin over 1 year of deferasirox treatment was
significantly correlated with a decrease in serum ALT, a finding that
has been observed with deferasirox in other patient popula-
tions.24-26 This suggests that the management of iron overload with
chelation therapy in patients with AA may have the potential to
improve clinical outcomes. Further prospective studies are neces-
sary to investigate the clinical benefits of deferasirox on liver and
other organ function.
As LPI is redox-active, it increases the risk of reactive oxygen
species production and can increase oxidative stress,27,28 which
may cause oxidation of lipids, proteins, and DNA, cell death, and
organ damage.29 Chelation therapy with deferasirox has been
shown to produce sustained reduction in LPI in patients with
	-thalassemia30 and MDS31-33; however, this is the first time that
LPI levels have been assessed in patients with AA. Of note, in
contrast to what has been observed in patients with 	-thalassemia
and MDS, baseline LPI levels were within the normal range
( 0.4M17) in this AA population, despite high serum ferritin
levels. The mechanism for this is conjectural at present, but
ineffective erythropoiesis is known to contribute to the formation
of non-transferrin-bound iron and therefore, presumably, to LPI
Figure 3. Mean absolute neutrophil and platelet counts during deferasirox
treatment.
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formation. The relative lack of ineffective erythropoiesis in AA,
compared with 	-thalassemia major or MDS, may lead to a slower
rate of iron release from bone marrow macrophages and hence a
greater chance of released iron binding to transferrin.
Twenty-eight patients with AA (24.1%) discontinued during the
1-year treatment period, primarily the result of the occurrence of
AEs; this rate is comparable with that of the overall EPIC
population (20.4%).15 Approximately 55% of patients with AA
experienced drug-related AEs; the most common were gastrointes-
tinal disorders and rash, as could be anticipated from previous
experience with deferasirox.12,13,34 Although more than 95% of AEs
were mild or moderate in nature, they may still have had a potential
impact on patients’ quality of life; however, this was not assessed in
the AA population using validated quality-of-life questionnaires.
The incidence of drug-related AEs was similar to that observed in
the overall EPIC population.15 As only a few, smaller studies have
been conducted with other iron chelators in patients with AA, it is
difficult to compare the safety profile of deferasirox in this
population with any other iron chelator. Eleven patients had a
deferasirox dose reduction because of an AE, but there were no
serious AEs or deaths considered related to study drug. Absolute
neutrophil and platelet counts remained stable during deferasirox
treatment, and there were no cases of drug-related cytopenias,
which is important because AA patients may develop or have
worsened cytopenias with progression of their underlying disease.
Nevertheless, it is advisable to monitor blood counts on a monthly
basis when deferasirox is being administered to patients with AA.
Although 25% of AA patients had an increase in serum creatinine
more than 33% above baseline and more than ULN on 2 consecu-
tive visits, there were no progressive increases. The only factor
identified that had a significant impact on serum creatinine during
the study was concomitant use of the immunosuppressive agent
cyclosporine, a drug with a well-recognized potential to impair
renal function.35 Careful monitoring of renal function is necessary
in patients with AA who are receiving concomitant cyclosporine
and deferasirox.
In conclusion, these data demonstrate that 1 year of treatment
with deferasirox was generally effective in reducing iron burden
and well tolerated in a large cohort of patients with AA and
transfusional iron overload. In line with other chronically trans-
fused patients,12,16 the reduction in serum ferritin was a function of
transfusional iron intake and deferasirox dose, with higher defera-
sirox doses required to decrease iron burden in patients with higher
iron intake.
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